Board Meeting Details

The Board of Directors meeting was held on November 05, 2026 through video conferencing deemed to be held at 605, 6th Floor, Rupa Solitaire Building, Millennium Business Park, Thane, Navi Mumbai, Maharashtra, India, 400110. The meeting commenced at 1:35 PM and concluded at 5:45 PM.

Key Decisions Approved

The Board considered and approved:

  • The Un-Audited Financial Results for the quarter and half year ended September 30, 2026, prepared on a Standalone & Consolidated basis
  • Limited Review Report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Trading Window Closure

The trading window for dealing in the Company's shares has been closed effective October 01, 2026, and shall continue to remain closed until 48 hours after the announcement of the un-audited financial results.

Standalone Financial Performance (Rs in lakhs)

Quarter Ended September 30, 2026:

  • Revenue from operations: ₹899.65
  • Total income: ₹899.65
  • Total expenses: ₹767.96
  • Profit before tax: ₹131.69
  • Tax expense: ₹33.68 (Current tax: ₹26.19, Deferred tax: ₹7.49)
  • Net profit after tax: ₹98.01
  • Earnings per share (Basic & Diluted): ₹0.29

Half Year Ended September 30, 2026:

  • Revenue from operations: ₹2,018.03
  • Total income: ₹2,018.03
  • Total expenses: ₹1,622.14
  • Profit before tax: ₹395.89
  • Tax expense: ₹199.01 (Current tax: ₹98.33, Deferred tax: ₹100.67)
  • Net profit after tax: ₹196.88
  • Earnings per share (Basic & Diluted): ₹0.57

Comparative Performance (Quarter):

  • Q2 FY26 Revenue: ₹518.33 vs Q2 FY27: ₹899.65 (73.6% increase)
  • Q2 FY26 Net profit: ₹17.84 vs Q2 FY27: ₹98.01 (449% increase)

Consolidated Financial Performance (Rs in lakhs)

Half Year Ended September 30, 2026:

  • Revenue from operations: ₹2,708.58
  • Other income: ₹6.39
  • Total income: ₹2,714.98
  • Total expenses: ₹2,307.59
  • Profit before tax: ₹407.39
  • Tax expense: ₹222.11 (Current tax: ₹101.28, Deferred tax: ₹120.83)
  • Net profit after tax: ₹185.28
  • Earnings per share (Basic & Diluted): ₹0.54
  • Minority interest share: ₹3.92

Subsidiaries Included:

1. Global Technologies Limited (Holding Company)

2. Miljon Medi App Private Limited (95.00% holding)

3. Innopharma Healthcare Private Limited (51.00% holding)

Auditor's Review Report

Bansilal Shah & Co., Chartered Accountants (FRN No: 000384W) conducted limited review and issued qualified opinion noting:

  • Inventory register maintained is not updated with details for quantity inwards and quantity outwards, movement of the inventory
  • For consolidated results, accounts of subsidiaries have not been reviewed by auditors who relied upon financial statements drafted by subsidiary management

Financial Position (Standalone as at September 30, 2026)

  • Total assets: ₹7,196.90 lakhs
  • Non-current assets: ₹5,984.22 lakhs (including Property, plant and equipment: ₹382.45, Intangible assets: ₹1,049.88, Intangible assets under development: ₹2,552.18)
  • Current assets: ₹1,212.68 lakhs
  • Total equity: ₹5,785.23 lakhs
  • Total liabilities: ₹1,236.94 lakhs

Cash Flow Statements (Half Year Ended September 30, 2026)

Standalone:

  • Net cash from operating activities: ₹249.67
  • Net cash used in investing activities: ₹(715.04)
  • Net cash from financing activities: ₹464.95
  • Net decrease in cash: ₹(0.42)

Consolidated:

  • Net cash from operating activities: ₹276.64
  • Net cash used in investing activities: ₹(805.32)
  • Net cash from financing activities: ₹520.06
  • Net decrease in cash: ₹(8.62)

Additional Notes

  • Debtors, Creditors & Loan Balances are subject to confirmations
  • Previous period figures have been re-grouped/re-classified wherever necessary
  • The format complies with SEBI Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 and July 5, 2016
  • Financial results prepared in accordance with Indian Accounting Standards (Ind AS)